Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Recruiting · NCT06015880 · Registry updated 2026-07-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, high grade B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 | 2026-07-09 | NCT06015880 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Institute (NCI) | 3015 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Case Western Reserve University | Cleveland | United States | 219 |
| City of Hope Comprehensive Cancer Center | Duarte | United States | 263 |
| Moffitt Cancer Center | Tampa | United States | 523 |
| Northwestern University | Chicago | United States | 727 |
| University of California Davis Comprehensive Cancer Center | Sacramento | United States | 299 |
| University of Oklahoma Health Sciences Center | Oklahoma City | United States | 491 |
| University of Virginia Cancer Center | Charlottesville | United States | 206 |
| Wake Forest University Health Sciences | Winston-Salem | United States | 330 |